Tenaya Therapeutics

This article from TIME discusses the treatment landscape for hypertrophic cardiomyopathy (HCM), including the next frontier of innovation to treat heart disease: gene therapy. Read more to hear from Dr. Milind Desai, Director at the Cleveland Clinic Hypertrophic Cardiomyopathy Center and an investigator for the MyPeak™-1 Phase 1b clinical trial: https://bit.ly/49D57Nh   #GeneTherapy #HeartDisease #HCM

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic heart disease that can result in dangerous arrhythmias and heart failure. For Tracy, ARVC’s deep impact is felt not only in her own experience, but in the lives of several members of her family. Read Tracy’s inspiring story about how life with ARVC has shaped her commitment to take nothing for granted: https://bit.ly/3I53T2e #PatientsFirst #HeartDisease #ARVC #cardiovasculardisease

#ICYMI: Members of #TeamTenaya represented our core value of #ScientificExcellence at #ASGCT2024. With seven presentations at the meeting, we were proud to highlight the ongoing advancement of our research and manufacturing capabilities. Posters are always available on our website here: https://bit.ly/3z9JNT7 #GeneTherapy #GeneEditing #heartdisease

Gene mutations can change the instructions the body uses to make proteins. The #PKP2 gene guides protein production needed for cell structures and signaling in the heart. A variation in this gene can lead to #ARVC. #Arrhythmia #ARVD #HeartDisease #GeneTherapy #Genetics

We capped #PrideMonth with a YOU LEAD event gathering Tenaya teammates for a bit of food, fun and lively conversation. The employee-led event featured activities intended to encourage celebration, reflection and inclusion. At Tenaya, "great company" means doing exciting work with outstanding people, in an inclusive environment where we can all be our authentic selves. #HappyPride #TeamTenaya #DiversityandInclusion

We announced changes to our Research leadership team. Congratulations to Kathy Ivey on her promotion to Senior Vice President of Research! Additionally, we announced that Chief Scientific Officer, Tim Hoey, will transition to an advisory role at Tenaya.    We’re also welcoming genetic therapy expert Barry Byrne, M.D., Ph.D., to our Scientific Advisory Board   Learn more in our press release: https://bit.ly/3zouiHf   #TeamTenaya

Tenaya CEO Faraz Ali spoke to CGTLive about our innovations in gene therapy and gene editing, such as capsid design and manufacturing. Check out the full article below. 👇

Congratulations to Leone Patterson, Tenaya's Chief Financial and Business Officer, for being recognized by BoardProspects as one of “75 LGBTQ+ Board Members Making a Difference.” In celebration of #PrideMonth, the June 2024 issue spotlights the contributions of top LGBTQ+ directors across the United States, in partnership with The Association of LGBTQ+ Corporate Directors. View the full report: https://lnkd.in/e2KS6v4k   #DiversityAndInclusion #Pride #LGBTleadership

From Cell & Gene: Tenaya Chief Scientific Officer Tim Hoey spoke to Editor-in-Chief Erin Harris about our progress with TN-401, our investigational gene therapy for the treatment for arrhythmogenic right ventricular cardiomyopathy (ARVC) patients with PKP2 mutations. Tim also shared insights about our broader pipeline, the transformative impact gene therapy could have in heart disease and why AAV9 is our capsid of choice for this indication. Read more: https://lnkd.in/gUnB9qFp   #GeneTherapy #ScientificExcellence #PatientsFirst #ARVC #heartdisease

Tenaya CEO Faraz Ali will give a presentation at the TD Cowen Genetic Medicines & RNA Summit this Friday, June 21. Tune in to the live webcast: https://bit.ly/3xyGxjH